UniQure Shares Fall on Mixed Trial Data
UniQure shares dropped after four-year data for its Huntington disease gene therapy missed statistical goals for slowing progression. The trial showed mixed results compared with a control group, raising questions about its pending US application.
Xurve View
Insights:
Xurve View
UNIQURE NV shares plummeted 40% on Tuesday after four-year data for its Huntington's disease gene therapy fell short of the goal to slow progression. The drop follows the Netherlands-based biotech's application for approval in the United States.
